Because BPC-157 has not been extensively studied in humans, there is no established safe dose, nor if there is any proven efficacy of this compound to treat specific medical conditions
Semaglutide is not recommended for people with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2
Though many of our patients with MASH and type 2 diabetes are already on GLP-1 agonists, if the FDA expands the indications of GLP-1 agonists to include MASH, this may expand drug eligibility for patients, she adds
A compromised skin barrier leads to a host of health and skin concerns, including dry skin, inflammatory conditions, and aging signs
Providers consider factors such as medical history, weight loss goals, side effect tolerance, and overall metabolic health before recommending treatment
Nat Rev Rheumatol 13(1):2540